SCHEMBL6644222

SCHEMBL6644222

Cc1ccc(C(=O)Nc2ccc(NC(=O)C(C)c3ccccn3)cc2)c(N2CCC(C)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
NPY2R P49146 2/20 0.44
GRM4 Q14833 1/20 0.43
ADRB2 P07550 1/20 0.42
ADRB1 P08588 1/20 0.42
ADRB3 P13945 1/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
MAPT P10636 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 3/20 0.39
GLA P06280 1/20 0.39
MCL1 Q07820 1/20 0.39
LMNA P02545 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6646552 0.87 ALDH1A1 (0.45) ALDH1A1GRM4ADRB2ADRB1ADRB3
SCHEMBL6645148 0.86 ALDH1A1 (0.46) ALDH1A1NPY2RGRM4ADRB2ADRB1
SCHEMBL6646638 0.85 ALDH1A1 (0.48) ALDH1A1NPY2RGRM4KMT2AMEN1
SCHEMBL6644659 0.82 NPC1 (0.55) ALDH1A1GRM4KMT2AMEN1MAPT
SCHEMBL6643855 0.81 ALDH1A1 (0.48) ALDH1A1NPY2RGRM4ADRB2ADRB1
SCHEMBL6649926 0.80 OGA (0.49) ALDH1A1GRM4ADRB2ADRB1ADRB3
SCHEMBL7199389 0.79 MAPT (0.50) ALDH1A1KMT2AMEN1MAPTSMN1; SMN2
SCHEMBL6646205 0.79 RAB9A (0.49) ALDH1A1GRM4ADRB2ADRB1ADRB3
SCHEMBL6646885 0.79 KMT2A (0.52) ALDH1A1KMT2AMEN1MAPTSMN1; SMN2
SCHEMBL6645235 0.79 GRM4 (0.50) ALDH1A1GRM4ADRB2ADRB1ADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR ALDH1A1 2174/4885NPY2R 404/4885GRM4 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.